Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CONTRAFECT CorpCFRX · Entity 116797 | Director | May 17, 2022 | May 18, 2022 |
| Lucid Diagnostics Inc.LUCD · Entity 6375 | Director · Chief Executive Officer | February 20, 2026 | February 25, 2026 |
| PAVmed Inc.PAVM · Entity 7317 | Director · Chairman and CEO | April 02, 2026 | April 03, 2026 |
| Viveon Health Acquisition Corp.VHAQ · Entity 138648 | Director | December 23, 2020 | December 29, 2020 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CONTRAFECT Corp
Report date May 17, 2022 · Filed May 18, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.35 · Expires 2032-05-17 | Direct | 42,000 |
Reported balance
After 2022-05-17 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-05-17 · Grant · Acquired 42,000 · Balance 42,000 F1: Grant award made under the ContraFect Corporation 2014 Omnibus Incentive Plan. Grant vests over one year, 25% at the end of each quarter following the vesting commencement date. |
Filing footnotes · ownership attribution and instrument terms
F1: Grant award made under the ContraFect Corporation 2014 Omnibus Incentive Plan. Grant vests over one year, 25% at the end of each quarter following the vesting commencement date.
Lucid Diagnostics Inc.
Report date February 20, 2026 · Filed February 25, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 3,636,627 |
Reported balance
After 2026-02-20 transaction · row 1
1 source rowRow 1 · 2026-02-20 · Grant · Acquired 2,170,000 · Balance 3,636,627 F1: Represents restricted stock granted to the reporting person under the Issuer's 2018 Equity Plan with a single vesting date of May 20, 2029. Such restricted stock is subject to forfeiture if the requisite service period is not completed. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents restricted stock granted to the reporting person under the Issuer's 2018 Equity Plan with a single vesting date of May 20, 2029. Such restricted stock is subject to forfeiture if the requisite service period is not completed.
PAVmed Inc.
Report date April 02, 2026 · Filed April 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 357,614 |
Reported balance
After 2026-04-02 transaction · row 1
1 source rowRow 1 · 2026-04-02 · Grant · Acquired 350,000 · Balance 357,614 F1: Represents restricted stock granted to the reporting person under the Issuer's Seventh Amended and Restated 2014 Long-Term Incentive Equity Plan with a single vesting date of May 20, 2029. Such restricted stock is subject to forfeiture if the requisite service period is not completed. |
| Common StockSEC Table I · non-derivative | IndirectBy daughter | 5 |
Reported balance
Holding disclosure · report date 2026-04-02 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 5 |
| Common StockSEC Table I · non-derivative | IndirectBy son | 5 |
Reported balance
Holding disclosure · report date 2026-04-02 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 5 |
| Common StockSEC Table I · non-derivative | IndirectBy Pavilion Venture Partners LLC | 9,904 |
Reported balance
Holding disclosure · report date 2026-04-02 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 9,904 F2: Dr. Aklog is a member and sole manager of Pavilion Venture Partners LLC, and therefore has sole voting and dispositive power over the securities held by this entity. Dr. Aklog disclaims beneficial ownership of securities held by this entity, except to the extent of his proportionate pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectBy HCFP/AG LLC | 45 |
Reported balance
Holding disclosure · report date 2026-04-02 · row 5
Holding and transaction disclosures are not merged.
1 source rowRow 5 · Balance 45 F3: Dr. Aklog is a co-manager of HCFP/AG LLC, and therefore has joint voting and dispositive power over the securities held by this entity. Dr. Aklog disclaims beneficial ownership of securities held by this entity, except to the extent of his proportionate pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents restricted stock granted to the reporting person under the Issuer's Seventh Amended and Restated 2014 Long-Term Incentive Equity Plan with a single vesting date of May 20, 2029. Such restricted stock is subject to forfeiture if the requisite service period is not completed.
F2: Dr. Aklog is a member and sole manager of Pavilion Venture Partners LLC, and therefore has sole voting and dispositive power over the securities held by this entity. Dr. Aklog disclaims beneficial ownership of securities held by this entity, except to the extent of his proportionate pecuniary interest therein.
F3: Dr. Aklog is a co-manager of HCFP/AG LLC, and therefore has joint voting and dispositive power over the securities held by this entity. Dr. Aklog disclaims beneficial ownership of securities held by this entity, except to the extent of his proportionate pecuniary interest therein.
Viveon Health Acquisition Corp.
Report date December 23, 2020 · Filed December 29, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, par value $0.0001 per shareSEC Table I · non-derivative | Direct | 27,000 |
Reported balance
After 2020-12-23 transaction · row 1
1 source rowRow 1 · 2020-12-23 · Other · Acquired 27,000 · Balance 27,000 F1: Represents founders shares transferred to Mr. Aklog from Viveon Health LLC, the sponsor of the Issuer, for Mr. Aklog's service as an independent director of the Issuer. There was no consideration paid in the transfer. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents founders shares transferred to Mr. Aklog from Viveon Health LLC, the sponsor of the Issuer, for Mr. Aklog's service as an independent director of the Issuer. There was no consideration paid in the transfer.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 15, 2016 Filed Sep 19, 2016 23:12 UTC | PAVmed Inc. PAVM · Entity 7317 | PurchaseCommon Stock | 300 | $13.95 | $4,186.14 |
DisclosureSEC source: 0001094891-16-000612 · edgar.xml · nonDerivative · entry 1 Aklog Lishan · CIK 0001665074 · Director · Chairman and CEO · 10% owner HCFP/Capital Partners III LLC · CIK 0001665111 · 10% owner Pavilion Venture Partners LLC · CIK 0001665114 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,100 Read SEC document |
| September 14, 2016 Filed Sep 16, 2016 16:01 UTC | PAVmed Inc. PAVM · Entity 7317 | PurchaseWarrants · Derivative | 200 | $8.00 Strike: $5.00 | $1,600.00 |
DisclosureSEC source: 0001094891-16-000610 · edgar.xml · derivative · entry 16 Aklog Lishan · CIK 0001665074 · Director · Chairman and CEO · 10% owner HCFP/Capital Partners III LLC · CIK 0001665111 · 10% owner Pavilion Venture Partners LLC · CIK 0001665114 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,150 Underlying: Common Stock · 200 shares Expires 2022-01-29 Read SEC document |
| September 14, 2016 Filed Sep 16, 2016 16:01 UTC | PAVmed Inc. PAVM · Entity 7317 | PurchaseCommon Stock | 200 | $14.45 | $2,890.00 |
DisclosureSEC source: 0001094891-16-000610 · edgar.xml · nonDerivative · entry 7 Aklog Lishan · CIK 0001665074 · Director · Chairman and CEO · 10% owner HCFP/Capital Partners III LLC · CIK 0001665111 · 10% owner Pavilion Venture Partners LLC · CIK 0001665114 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,800 Read SEC document |
| September 13, 2016 Filed Sep 16, 2016 16:01 UTC | PAVmed Inc. PAVM · Entity 7317 | PurchaseWarrants · Derivative | 300 | $7.00 Strike: $5.00 | $2,100.00 |
DisclosureSEC source: 0001094891-16-000610 · edgar.xml · derivative · entry 15 Aklog Lishan · CIK 0001665074 · Director · Chairman and CEO · 10% owner HCFP/Capital Partners III LLC · CIK 0001665111 · 10% owner Pavilion Venture Partners LLC · CIK 0001665114 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,950 Underlying: Common Stock · 300 shares Expires 2022-01-29 Read SEC document |
| September 13, 2016 Filed Sep 16, 2016 16:01 UTC | PAVmed Inc. PAVM · Entity 7317 | PurchaseWarrants · Derivative | 500 | $6.99 Strike: $5.00 | $3,495.45 |
DisclosureSEC source: 0001094891-16-000610 · edgar.xml · derivative · entry 14 Aklog Lishan · CIK 0001665074 · Director · Chairman and CEO · 10% owner HCFP/Capital Partners III LLC · CIK 0001665111 · 10% owner Pavilion Venture Partners LLC · CIK 0001665114 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,650 Underlying: Common Stock · 500 shares Expires 2022-01-29 Read SEC document |
| September 13, 2016 Filed Sep 16, 2016 16:01 UTC | PAVmed Inc. PAVM · Entity 7317 | PurchaseCommon Stock | 500 | $12.50 | $6,252.00 |
DisclosureSEC source: 0001094891-16-000610 · edgar.xml · nonDerivative · entry 6 Aklog Lishan · CIK 0001665074 · Director · Chairman and CEO · 10% owner HCFP/Capital Partners III LLC · CIK 0001665111 · 10% owner Pavilion Venture Partners LLC · CIK 0001665114 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,600 Read SEC document |
| September 13, 2016 Filed Sep 16, 2016 16:01 UTC | PAVmed Inc. PAVM · Entity 7317 | PurchaseCommon Stock | 200 | $12.88 | $2,576.00 |
DisclosureSEC source: 0001094891-16-000610 · edgar.xml · nonDerivative · entry 5 Aklog Lishan · CIK 0001665074 · Director · Chairman and CEO · 10% owner HCFP/Capital Partners III LLC · CIK 0001665111 · 10% owner Pavilion Venture Partners LLC · CIK 0001665114 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,100 Read SEC document |
| September 13, 2016 Filed Sep 16, 2016 16:01 UTC | PAVmed Inc. PAVM · Entity 7317 | PurchaseCommon Stock | 100 | $12.48 | $1,247.80 |
DisclosureSEC source: 0001094891-16-000610 · edgar.xml · nonDerivative · entry 4 Aklog Lishan · CIK 0001665074 · Director · Chairman and CEO · 10% owner HCFP/Capital Partners III LLC · CIK 0001665111 · 10% owner Pavilion Venture Partners LLC · CIK 0001665114 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,900 Read SEC document |
| September 01, 2016 Filed Sep 16, 2016 16:01 UTC | PAVmed Inc. PAVM · Entity 7317 | PurchaseWarrants · Derivative | 300 | $7.99 Strike: $5.00 | $2,397.60 |
DisclosureSEC source: 0001094891-16-000610 · edgar.xml · derivative · entry 13 Aklog Lishan · CIK 0001665074 · Director · Chairman and CEO · 10% owner HCFP/Capital Partners III LLC · CIK 0001665111 · 10% owner Pavilion Venture Partners LLC · CIK 0001665114 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,150 Underlying: Common Stock · 300 shares Expires 2022-01-29 Read SEC document |
| September 01, 2016 Filed Sep 16, 2016 16:01 UTC | PAVmed Inc. PAVM · Entity 7317 | PurchaseCommon Stock | 200 | $13.98 | $2,795.50 |
DisclosureSEC source: 0001094891-16-000610 · edgar.xml · nonDerivative · entry 3 Aklog Lishan · CIK 0001665074 · Director · Chairman and CEO · 10% owner HCFP/Capital Partners III LLC · CIK 0001665111 · 10% owner Pavilion Venture Partners LLC · CIK 0001665114 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,800 Read SEC document |
| September 01, 2016 Filed Sep 16, 2016 16:01 UTC | PAVmed Inc. PAVM · Entity 7317 | PurchaseCommon Stock | 200 | $14.49 | $2,898.00 |
DisclosureSEC source: 0001094891-16-000610 · edgar.xml · nonDerivative · entry 2 Aklog Lishan · CIK 0001665074 · Director · Chairman and CEO · 10% owner HCFP/Capital Partners III LLC · CIK 0001665111 · 10% owner Pavilion Venture Partners LLC · CIK 0001665114 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,600 Read SEC document |
| September 01, 2016 Filed Sep 16, 2016 16:01 UTC | PAVmed Inc. PAVM · Entity 7317 | PurchaseCommon Stock | 100 | $14.44 | $1,444.00 |
DisclosureSEC source: 0001094891-16-000610 · edgar.xml · nonDerivative · entry 1 Aklog Lishan · CIK 0001665074 · Director · Chairman and CEO · 10% owner HCFP/Capital Partners III LLC · CIK 0001665111 · 10% owner Pavilion Venture Partners LLC · CIK 0001665114 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,400 Read SEC document |
| August 23, 2016 Filed Sep 19, 2016 23:12 UTC | PAVmed Inc. PAVM · Entity 7317 | PurchaseWarrants · Derivative | 100 | $6.35 Strike: $5.00 | $635.00 |
DisclosureSEC source: 0001094891-16-000612 · edgar.xml · derivative · entry 12 Aklog Lishan · CIK 0001665074 · Director · Chairman and CEO · 10% owner HCFP/Capital Partners III LLC · CIK 0001665111 · 10% owner Pavilion Venture Partners LLC · CIK 0001665114 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,250 Underlying: Common Stock · 100 shares Expires 2022-01-29 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.